Helena Earl

Oral poly(ADP-ribose) polymerase inhibitor olaparib in patients with BRCA1 or BRCA2 mutations and advanced breast cancer: a proof-of-concept trial

Andrew Tutt, Mark E. Robson, Judy E. Garber et al. · The Lancet · 2010 · 1.6K citations

Medicine, Oncology, Pharmacotherapy +13

Association between CD8+ T-cell infiltration and breast cancer survival in 12 439 patients

Hager R. Ali, Elena Provenzano, Sarah‐Jane Dawson et al. · Annals of Oncology · 2014 · 790 citations · Full text

Medicine, Immunology, Oncology +14

Baseline Cardiovascular Risk Assessment in Cancer Patients Scheduled to Receive Cardiotoxic Cancer Therapies: A Position Statement and New Risk Assessment Tools from the Cardio-Oncology Study Group of the Heart Failure Association of the European Society of Cardiology in Collaboration with the International Cardio-Oncology Society

Alexander R. Lyon, Susan Dent, Susannah Stanway et al. · European Journal of Heart Failure · 2020 · 770 citations · Full text

Medicine, Cardiology, Oncology +16

Multi-omic machine learning predictor of breast cancer therapy response

Stephen‐John Sammut, Mireia Crispin‐Ortuzar, Suet‐Feung Chin et al. · Nature · 2021 · 642 citations · Full text

Medicine, Cancer Biology, Oncology +17

aTTom: Long-term effects of continuing adjuvant tamoxifen to 10 years versus stopping at 5 years in 6,953 women with early breast cancer.

Richard Gray, Daniel Rea, Kelly Handley et al. · Journal of Clinical Oncology · 2013 · 450 citations

Medicine, Oncology, Breast Oncology +11